Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions
暂无分享,去创建一个
[1] H. Stefánsson,et al. Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease , 2015, Circulation.
[2] L. Frölich,et al. The metabolism hypothesis of Alzheimer’s disease: from the concept of central insulin resistance and associated consequences to insulin therapy , 2015, Journal of Neural Transmission.
[3] A. Goate,et al. Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis , 2015, Biological Psychiatry.
[4] X. Wang,et al. Polymorphism of the OLR1 3'UTR potential microRNA binding site and risk of Alzheimer's disease: a meta-analysis. , 2014, Genetics and molecular research : GMR.
[5] B. Strooper,et al. Lessons from a Failed γ-Secretase Alzheimer Trial , 2014, Cell.
[6] K. M. Deneen,et al. Altered effective connectivity patterns of the default mode network in Alzheimer's disease: An fMRI study , 2014, Neuroscience Letters.
[7] W. Lukiw,et al. Deficits in the miRNA-34a-regulated endogenous TREM2 phagocytosis sensor-receptor in Alzheimer's disease (AD); an update , 2014, Front. Aging Neurosci..
[8] E. Siemers,et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[9] D. Galimberti,et al. Circulating miRNAs as potential biomarkers in Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.
[10] B. Ray,et al. MicroRNA-339-5p Down-regulates Protein Expression of β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 (BACE1) in Human Primary Brain Cultures and Is Reduced in Brain Tissue Specimens of Alzheimer Disease Subjects* , 2013, The Journal of Biological Chemistry.
[11] B. de Strooper,et al. The composition of the γ-secretase complex defines its Aβ product profile , 2013, Molecular Neurodegeneration.
[12] E. Siemers,et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. , 2013, The New England journal of medicine.
[13] M. Mintun,et al. Exploratory analyses of regional human brain distribution of the PET tau tracer F18-labeled T807 (AV-1541) in subjects with normal cognitive function or cognitive impairment thought to be due to Alzheimer's disease , 2013, Alzheimer's & Dementia.
[14] R. Singaraja. TREM2: a new risk factor for Alzheimer's disease , 2013, Clinical genetics.
[15] B. Hyman,et al. Mechanisms of protein seeding in neurodegenerative diseases. , 2013, JAMA neurology.
[16] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[17] Christine Van Broeckhoven,et al. Genetic insights in Alzheimer's disease , 2013, The Lancet Neurology.
[18] A. Singleton,et al. TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.
[19] M. Daly,et al. Variant TREM2 as risk factor for Alzheimer's disease. , 2013, The New England journal of medicine.
[20] W. Jagust,et al. Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load. , 2013, Current Alzheimer research.
[21] Ole A. Andreassen,et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.
[22] L. Mucke,et al. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.
[23] B. Ray,et al. MicroRNA-153 Physiologically Inhibits Expression of Amyloid-β Precursor Protein in Cultured Human Fetal Brain Cells and Is Dysregulated in a Subset of Alzheimer Disease Patients* , 2012, The Journal of Biological Chemistry.
[24] Stephen J. DeArmond,et al. Purified and synthetic Alzheimer’s amyloid beta (Aβ) prions , 2012, Proceedings of the National Academy of Sciences.
[25] Hermona Soreq,et al. Threshold-independent meta-analysis of Alzheimer's disease transcriptomes shows progressive changes in hippocampal functions, epigenetics and microRNA regulation. , 2012, Current Alzheimer research.
[26] Mark Jenkinson,et al. Structural MRI changes detectable up to ten years before clinical Alzheimer's disease , 2012, Neurobiology of Aging.
[27] W. Thies,et al. 2008 Alzheimer’s disease facts and figures , 2008, Alzheimer's & Dementia.
[28] S. Robinson,et al. Reactive astrocytes give neurons less support: implications for Alzheimer's disease , 2012, Neurobiology of Aging.
[29] Menno P. Witter,et al. Trans-Synaptic Spread of Tau Pathology In Vivo , 2012, PloS one.
[30] J. Schneider,et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.
[31] T. Wyss-Coray,et al. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. , 2012, Cold Spring Harbor perspectives in medicine.
[32] P. Reddy,et al. Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease , 2011, Brain Research.
[33] P. Wong,et al. Amyloid precursor protein processing and Alzheimer's disease. , 2011, Annual review of neuroscience.
[34] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[35] Nick C Fox,et al. Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.
[36] P. Reddy,et al. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. , 2011, Biochimica et biophysica acta.
[37] Michael D. Greicius,et al. Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. , 2011, Cerebral cortex.
[38] Jürgen Götz,et al. Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease , 2011, Nature Reviews Neuroscience.
[39] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[40] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .
[41] Huaxi Xu,et al. APP processing in Alzheimer's disease , 2011, Molecular Brain.
[42] Julie A. Harris,et al. Transsynaptic Progression of Amyloid-β-Induced Neuronal Dysfunction within the Entorhinal-Hippocampal Network , 2010, Neuron.
[43] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[44] Hilkka Soininen,et al. J-ADNI and selection of cognition measures , 2010, Alzheimer's & Dementia.
[45] Harald Hampel,et al. Biological markers of amyloid β-related mechanisms in Alzheimer's disease , 2010, Experimental Neurology.
[46] B. Bendlin,et al. Midlife Predictors of Alzheimer's Disease , 1999 .
[47] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[48] K. Reymann,et al. Mechanism of amyloid plaque formation suggests an intracellular basis of Aβ pathogenicity , 2010, Proceedings of the National Academy of Sciences.
[49] D. Teplow,et al. Structure-neurotoxicity relationships of amyloid β-protein oligomers , 2009, Neuroscience Research.
[50] R. Martins,et al. Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease , 2009, Journal of neurochemistry.
[51] Nick C. Fox,et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease , 2009, Neurobiology of Aging.
[52] G. Stebbins,et al. Diffusion Tensor Imaging in Alzheimer’s Disease and Mild Cognitive Impairment , 2009, Behavioural neurology.
[53] Nick C Fox,et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.
[54] Keith A. Johnson,et al. Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia , 2009, Neuron.
[55] Thomas Arendt,et al. Synaptic degeneration in Alzheimer’s disease , 2009, Acta Neuropathologica.
[56] Berislav V. Zlokovic,et al. Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease , 2009, Acta Neuropathologica.
[57] Nick C Fox,et al. Hippocampal atrophy rates in Alzheimer disease , 2009, Neurology.
[58] P. Hajduk,et al. Structural characterization of a soluble amyloid beta-peptide oligomer. , 2009, Biochemistry.
[59] J. Morris,et al. The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.
[60] Rachel L. Mistur,et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[61] E. Koo,et al. Amyloid Precursor Protein Trafficking, Processing, and Function* , 2008, Journal of Biological Chemistry.
[62] H. Vinters,et al. Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes. , 2008, The American journal of pathology.
[63] Daniel L. Rubin,et al. Network Analysis of Intrinsic Functional Brain Connectivity in Alzheimer's Disease , 2008, PLoS Comput. Biol..
[64] R O Weller,et al. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology , 2008, Neuropathology and applied neurobiology.
[65] R. Carare,et al. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. , 2008, Brain pathology.
[66] M. Beal,et al. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. , 2008, Trends in molecular medicine.
[67] Kuncheng Li,et al. Altered functional connectivity in early Alzheimer's disease: A resting‐state fMRI study , 2007, Human brain mapping.
[68] F. Schmitt,et al. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment , 2007, Neurology.
[69] D. Selkoe,et al. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.
[70] Nick C Fox,et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study , 2006, The Lancet Neurology.
[71] F. Schmitt,et al. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment , 2006, Neurobiology of Aging.
[72] J. Götz,et al. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? , 2006, Journal of neurochemistry.
[73] C. Jack,et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI , 2005, Neurology.
[74] N. Bohnen,et al. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease , 2005, Neuroscience Letters.
[75] L. Mosconi,et al. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[76] R. Tanzi,et al. Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.
[77] I. Grundke‐Iqbal,et al. Tau pathology in Alzheimer disease and other tauopathies. , 2005, Biochimica et biophysica acta.
[78] M. Greicius,et al. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI , 2004, Proc. Natl. Acad. Sci. USA.
[79] S. Hoyer,et al. Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? , 2004, Journal of Neurology.
[80] E. Mandelkow,et al. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses , 2003, Neurobiology of Aging.
[81] Jean-Claude Baron,et al. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons , 2003, NeuroImage.
[82] Michel Goedert,et al. Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-β structure , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[83] C. Haass,et al. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts , 2003, The Journal of cell biology.
[84] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[85] G. Alexander,et al. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.
[86] S. Hoyer,et al. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update , 2002, Journal of Neural Transmission.
[87] M. Kirkitadze,et al. Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. , 2002 .
[88] S. Laughlin,et al. An Energy Budget for Signaling in the Grey Matter of the Brain , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[89] S. Minoshima,et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease , 1999, Neurology.
[90] H. Soininen,et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease , 1997, Neuroreport.
[91] H. Braak,et al. Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.
[92] M. Bobinski,et al. Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.
[93] A. Crane,et al. Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[94] G. Glenner,et al. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.
[95] W J Schwartz,et al. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. , 1979, Science.
[96] E K Perry,et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.